AltPep Corporation’s SOBA-AD blood test has demonstrated promising accuracy in detecting Alzheimer’s disease (AD) in two independent studies. Published in the peer-reviewed journal Scientific Reports, the study evaluated 265 blinded plasma samples, achieving 100% sensitivity, >95% specificity, and >98% area under the curve in distinguishing AD patients from cognitively unimpaired controls.
The SOBA-AD test targets toxic soluble oligomers, early molecular triggers of amyloid diseases, aiming to identify AD patients years before symptoms manifest. This study builds on earlier research that analyzed 644 samples, consistently exhibiting high performance metrics.
The test’s unique feature is its ability to rationally target alpha-sheet protein structures found in toxic oligomers, distinguishing it from other technologies. The successful implementation at multiple locations highlights its potential as a biomarker for AD clinical trials and an earlier diagnostic tool to enable timely treatment.
In addition, the study included a more diverse sample population, supporting the potential for early detection in preclinical stages. Five CU controls tested positive, suggesting possible pre-symptomatic disease, although confirmatory data is pending.
Overall, the results support the SOBA-AD blood test as a promising tool for selective detection and confirmation of AD, potentially transforming the diagnosis and management of this devastating disease.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
